

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: Cristina Scielzo

POSITION TITLE: Group Leader - Division of Experimental Oncology – Malignant B cell biology and 3D modelling UNIT- IRCCS Hospital San Raffaele

EDUCATION/TRAINING:

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY
Università degli Studi di Genova, Genova Italy	Bachelor	2001	Biotechnology
Università Vita-Salute San Raffaele, Milan Italy	Master	2007	Biotechnology and Medical biology
Università degli Studi di Milano, Milan Italy	PhD	2012	Physiology

A. Personal Statement

During the past 15 years I have focused my research interests on the interplay between leukemic cells and the microenvironment. I made significant contributions to the study of relevant signaling pathways in Chronic lymphocytic leukemia (CLL), nowadays representing therapeutic targets in the clinical practice. I personally developed, or contributed to develop, CLL pre-clinical models and established new methods to study B cell function using innovative co-culture systems and imaging techniques. I optimized protocols for isolating different cell populations from tissues and peripheral blood and set up protocols for genetic modification of CLL cells. Several research labs are now routinely using the models and protocols that I have developed. Although I did not have the opportunity to spend long periods of time abroad, I experienced proficient visits to competitive labs at Harvard-Boston and Madrid, where I learned several new techniques, primarily for live cell imaging, and established long-term international collaborations. At my institute, I established fruitful collaborations with several labs leading to important scientific publications. In addition, I established several collaborations with researchers in Europe to develop my studies and write grant applications. Those years of experience in the field help me in thinking and design my future lines of research. Starting from 2016 I wrote grant application to start my independent career on this topic. Thanks to those funding I published last authors papers and I established multidisciplinary (bio-physicists and bio-engineers) collaboration in Italy and abroad. I pioneered new 3D in vitro models by establishing the first 3D Bioprinted long term culture for CLL primary cells (**Sbrana et al. [...] Scielzo. Front Immunol 2021**) and by optimizing dynamic growth in bioreactor in-vitro to predict patients' specific response to mobilizing agents (**Barbaglio et al. [...] Scielzo. Haematologica 2020**). Currently I have a skilled team composed by two post docs, 3 PhD student a research technician, a junior scientist, a master student in biotechnology, a fully equipped laboratory and fundamental collaborations with clinicians and physicists.

B. Positions, Scientific Appointments, and Honors

INSTITUTIONS	DIVISION/RESEARCH GROUP	LOCATION	POSITION	FROM YEAR	TO YEAR
IRCCS San Raffaele Scientific Institute	Malignant B cell biology and 3D modelling Unit - Division of Experimental Oncology	Milan-Italy	Group Leader	2020	present
IRCCS San Raffaele Scientific Institute	B cell neoplasia Unit - Division of Experimental Oncology	Milan-Italy	Project Leader	2016	2019
IRCCS San Raffaele Scientific Institute	Laboratory of Lymphoid Malignancies - Division of Molecular Oncology	Milan -Italy	Post Doc	2012	2015

CNIC (Fundación Centrom Nacional de Investigaciones Cardiovasculares Carlos III)	Microscopy Unit	Madrid-Spain	Visiting Scientist	2011	2011
Dana Farber Cancer Institute	Department of Medical Oncology	Boston USA	Visiting fellow	2003	2003

Awards and fundings:

2024-present. PNRR funded by Ministero della Salute. Title: "3D Bioprinting as a therapeutic innovation tool for precision oncology". Role: PI

2024-present. Investigator grant funded by AIRC (Associazione Italiana Ricerca sul Cancro). Title: "Deciphering and targeting mechanical adaptability for the treatment of chronic lymphocytic leukemia". Role: PI

2022 -2023. Grant funded by Alternative research and development foundation. Role: PI (topic: 3D modelling)

2021- 2023. Grant funded by European Haematology Association. Role: PI (topic: 3D modelling)

2019 - 2024. Investigator grant funded by AIRC. Role: PI (topic: Leukemia microenvironment)

2018. Grant funded by Leukemia Research Foundation Grant. Role: PI (topic: 3D modelling)

2017. Grant funded by Roche per la Ricerca Grant. Role: PI (topic: 3D modelling)

2016. MY FIRST funded by AIRC. Role: PI (topic Leukemia microenvironment)

2016-Extension 5xmille Research Program grant funded by AIRC. Role: Group Leader (topic Leukemia microenvironment)

Reviewing activities

Grants reviewer for funding agency: Bloodwise foundation (UK), The Fundação para a Ciência e a Tecnologia, I.P. (FCT), the Portuguese public funding agency for R&D, EHA grant, European reaserch Council.

Reviewer activity for peer-reviewed juornals: selected Journals: The journal of clinical investigation (JCI), Nature Communication Blood, Haematologica, Clinical Cancer Research, Leukemia, PLOS one, JOVE, Leukemia & Lymphoma, Life science, Frontiers group.

Associate Editor: Journal of leukocyte biology (JLB), Frontiers in Biomaterials Science for Regenerative Therapies. Guest Associate Editor: Frontiers in Medical Technology on the topic "3D Bioprinting for Human Disease Modelling and Therapeutic Screening".

C. Contributions to Science

Publication list:

h-index scopus 28

Citation index scopus 3,107

- Emerging Strategies in 3D Culture Models for Hematological Cancers. Barozzi D, **Scielzo C**. Hemasphere. 2023 Jul 27;7(8):e932. I.F. 9.1
- The Nanomechanical Properties of CLL Cells Are Linked to the Actin Cytoskeleton and Are a Potential Target of BTK Inhibitors. Sampietro M, Cassina V, Salerno D, Barbaglio F, Buglione E, Marrano CA, Campanile R, Scarfò L, Biedenweg D, Fregin B, Zamai M, Díaz Torres A, Labrador Cantarero V, Ghia P, Otto O, Mantegazza F, Caiolfa VR, **Scielzo C**. Hemasphere. 2023 Jul 21;7(8):e931. doi: 10.1097/HS9.0000000000000931 I.F. 9.1
- PYK2 is overexpressed in chronic lymphocytic leukaemia: A potential new therapeutic target. Sbrana FV, Fiordi B, Bordini J, Belloni D, Barbaglio F, Russo L, Scarfò L, Ghia P, **Scielzo C**. J Cell Mol Med. 2023 Feb;27(4):576-586. doi: 10.1111/jcmm.17688. Epub 2023 Feb 6 I.F. 5.3
- Design of a novel bioink suitable for the 3D printing of lymphoid cells. Ribezzi...**Scielzo*** & Farè*. Front. Biomater. Sci., 13 February 2023 ***co-corresponding** I.F. nd
- Protocol for generation of 3D bone marrow surrogate microenvironments in a rotary cell culture system. Belloni D, Ferrarini M, Ferrero E, Guzzeloni V, Barbaglio F, Ghia P, **Scielzo C**. STAR Protoc. 2022 Aug 10;3(3):101601. doi: 10.1016/j.xpro.2022.101601. eCollection 2022 Sep 16. I.F. 1.4
- 3D-STED Super-Resolution Microscopy Reveals Distinct Nanoscale Organization of the Hematopoietic Cell-

- Specific Lyn Substrate-1 (HS1) in Normal and Leukemic B Cells. Sampietro....**Scielzo*** & Caiolfa*. Front. Cell. Dev. Bio. 2021* **co-last authorship** I.F. 5.5
7. 3D Bioprinting Allows the Establishment of Long-Term 3D Culture Model for Chronic Lymphocytic Leukemia Cells. Sbrana.....**Scielzo**. Front Immunol 2021 I.F. 7.3
 8. Modeling the Leukemia Microenvironment *In Vitro*. **Scielzo C**, Ghia P. Front Oncol. 2020 Dec 17;10:607608. doi: 10.3389/fonc.2020.607608. eCollection 2020. I.F. 4.7
 9. B lymphocytes contribute to stromal reaction in pancreatic ductal adenocarcinoma. Minici C, Rigamonti E, Lanzillotta M, Monno A, Rovati L, Maehara T, Kaneko N, Deshpande V, Protti MP, De Monte L, **Scielzo C**, Crippa S, Arcidiacono PG, Dugnani E, Piemonti L, Falconi M, Pillai S, Manfredi AA, Della-Torre E. Oncoimmunology. 2020 Jul 16;9(1):1794359. doi: 10.1080/2162402X.2020.1794359. I.F. 8.10
 10. 3D co-culture model of chronic lymphocytic leukemia bone marrow microenvironment predicts patient-specific response to mobilizing agents. Barboglio F, Belloni D, Scarfò L, Sbrana FV, Ponzoni M, Bongiovanni L, Pavesi L, Zambroni D, Stamatopoulos K, Caiolfa VR, Ferrero E, Ghia P, **Scielzo C**. Haematologica. 2020 Jul 30;haematol.2020.248112. doi: 10.3324/haematol.2020.248112. I.F. 10.1
 11. Computational analysis of the evolutionarily conserved Missing In Metastasis/Metastasis Suppressor 1 gene predicts novel interactions, regulatory regions and transcriptional control. Petrov P, Sarapulov AV, Eöry L, **Scielzo C**, Scarfò L, Smith J, Burt DW, Mattila PK. Sci Rep. 2019 Mar 11;9(1):4155. I.F. 4.2 PMID: 30858428
 12. T-cell defects in patients with ARPC1B germline mutations account for combined immunodeficiency. Brigida I, Zoccolillo M, Cicalese MP, Pfajfer L, Barzaghi F, Scala S, Oleaga-Quintas C, Álvarez-Álvarez JA, Sereni L, Giannelli S, Sartirana C, Dionisio F, Pavesi L, Benavides-Nieto M, Basso-Ricci L, Capasso P, Mazzi B, Rosain J, Marcus N, Lee YN, Somech R, Degano M, Raiola G, Caorsi R, Picco P, Moncada Velez M, Khourieh J, Arias AA, Bousfiha A, Issekutz T, Issekutz A, Boisson B, Dobbs K, Villa A, Lombardo A, Neven B, Moshous D, Casanova JL, Franco JL, Notarangelo LD, **Scielzo C**, Volpi S, Dupré L, Bustamante J, Gattorno M, Aiuti A. Blood. 2018 Nov 29;132(22):2362-2374. I.F. 13.2. PMID: 30254128
 13. A retinoic acid-dependent stroma-leukemia crosstalk promotes chronic lymphocytic leukemia progression. Farinello D, Woznińska M, Lenti E, Genovese L, Bianchessi S, Migliori E, Sacchetti N, di Lillo A, Bertilaccio MTS, de Lalla C, Valsecchi R, Gleave SB, Lligé D, **Scielzo C**, Mauri L, Ciampa MG, Scarfò L, Bernardi R, Lazarevic D, Gonzalez-Farre B, Bongiovanni L, Campo E, Cerutti A, Ponzoni M, Pattini L, Caligaris-Cappio F, Ghia P, Brendolan A. Nat Commun. 2018 May 3;9(1):1787. I.F. 12.1. PMID: 29725010
 14. Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis. Gorini F, Azzimonti L, Delfanti G, Scarfò L, **Scielzo C**, Bertilaccio MT, Ranghetti P, Gulino A, Doglioni C, Di Napoli A, Capri M, Franceschi C, Caligaris-Cappio F, Ghia P, Bellone M, Dellabona P, Casorati G, de Lalla C. Blood. 2017 May 2 I.F. 13.2. PMID: 28465341
 15. Synthetic high-density lipoproteins as targeted monotherapy and with B-cell receptor and BCL2 agents for chronic lymphocytic leukemia. Kaylin McMahon*, **Cristina Scielzo***, Nick Angeloni, Lydia Scarfo, Pamela Ranghetti, Leo Gordon, Frank Giles, Colby Thaxton, and Paolo Ghia * **first authors equally contributed**. Oncotarget. 17 Feb 2017 I.F. 5.1. PMID: 28061439
 16. Functional differences between IgM and IgD signaling in chronic lymphocytic leukemia. Elisa ten Hacken, Mariela Sivina, Susan O'Brien, William G. Wierda, Alessandra Ferrajoli, Zeev Estrov, Michael J. Keating, Thomas Oellerich, **Cristina Scielzo**, Paolo Ghia, Federico Caligaris-Cappio and Jan A. Burger. J. Immunol June 2016 I.F. 5.8. PMID: 27534555
 17. Inhibition of Chronic Lymphocytic Leukemia Progression by Full-length Chromogranin A and its Nterminal Fragment in Mouse Models. Mimma Bianco, Anna Gasparri, Luca Generoso, Emma Assi, Barbara Colombo, Lydia Scarfò, Maria T.S. Bertilaccio, **Cristina Scielzo**, Pamela Ranghetti, Eleonora Dondossola, Maurilio Ponzoni, Federico Caligaris-Cappio, Paolo Ghia and Angelo Corti. Oncotarget. Jul 2016 I.F. 5.1. PMID: 27203389
 18. Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression. Galletti G, **Scielzo C**, Barboglio F, Rodriguez TV, Riba M, Lazarevic D, Cittaro D, Simonetti G, Ranghetti P, Scarfò L, Ponzoni M, Rocchi M, Corti A, Anselmo A, van Rooijen N, Klein C, Ries CH, Ghia P, De Palma M, Caligaris-Cappio F, Bertilaccio MT. Cell Rep. 2016 Feb 10. pii: S2211-1247(16)30020-1. I.F. 8.3. PMID: 26876171
 19. HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment. Valsecchi R, Coltella N, Belloni D, Ponente M, Ten Hacken E, **Scielzo C**, Scarfò L, Bertilaccio MT, Brambilla P, Lenti E, Martinelli Boneschi F, Brendolan A, Ferrero E, Ferrarini M, Ghia P, Tonon G, Ponzoni M, Caligaris Cappio F, Bernardi R. Blood. 2016 Jan 29. I.F. 13.2. PMID: 26825709
 20. Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia Cell Line. Agathangelidis A, Scarfò L, Barboglio F, Apollonio B, Bertilaccio MT, Ranghetti P, Ponzoni M, Leone G, De Pascali V, Pecciarini L, Ghia P, Caligaris-Cappio F, **Scielzo C***. PLoS One. 2015 Jun 25;10(6):e0130195 * **corresponding author** I.F. 3.6. PMID: 26110819

21. Apollonio B, Bertilaccio MT, Restuccia U, Ranghetti P, Barbaglio F, Ghia P, Caligaris-Cappio F, **Scielzo C***. From a 2DE-gel spot to protein function: lesson learned from HS1 in chronic lymphocytic leukemia. *J Vis Exp*. 2014 Oct 19;(92):e51942 * **corresponding author** I.F. 1,3. PMID: 25350848
22. How the microenvironment wires the natural history of chronic lymphocytic leukemia. Caligaris- Cappio F, Bertilaccio MT, **Scielzo C**. *Semin Cancer Biol*. 2014 Feb;24:43-8. I.F. 9,3. PMID: 23831274
23. Targeting B-cell anergy in chronic lymphocytic leukemia. Apollonio B, **Scielzo C**, Bertilaccio MT, TenHacken E, Scarfò L, Ranghetti P, Stevenson F, Packham G, Ghia P, Muzio M, Caligaris-Cappio F. *Blood*. 2013 May 9;121(19):3879-88, S1-8. I.F.13,2. PMID: 23460614
24. Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia. ten Hacken E *, **Scielzo C ***, Bertilaccio MT, Scarfò L, Apollonio B, Barbaglio F, Stamatopoulos K, Ponzoni M, Ghia P, Caligaris-Cappio F. *Blood*. 2013 Mar 21;121(12):2264-73. * **first authors equally contributed**. I.F.13,2. PMID: 23325840
25. Xenograft models of chronic lymphocytic leukemia: problems, pitfalls and future directions. Bertilaccio MT, **Scielzo C**, Simonetti G, Ten Hacken E, Apollonio B, Ghia P, Caligaris-Cappio F. *Leukemia*. 2013 Mar;27(3):534-40. I.F. 11,7. PMID: 23041721
26. General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. Fazi C, Scarfò L, Pecciarini L, Cottini F, Dagklis A, Janus A, Talarico A, **Scielzo C**, Sala C, Toniolo D, Caligaris-Cappio F, Ghia P. *Blood*. 2011 Dec 15;118(25):6618-25. I.F. 13,2. PMID: 21876118
27. The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia. **Scielzo C**, Apollonio B, Scarfò L, Janus A, Muzio M, Ten Hacken E, Ghia P, Caligaris-Cappio F. *Leukemia*. 2011 Nov;25(11):1760-7. I.F. 11,7. PMID: 21709686
28. CLL-like monoclonal B-cell lymphocytosis: are we all bound to have it? Scarfò L, Dagklis A, **Scielzo C**, Fazi C, Ghia P. *Semin Cancer Biol*. 2010 Dec;20(6):384-90. *Semin cancer*.2010.08.005. Review I.F. 7,436. PMID: 20816789
29. How the microenvironment shapes chronic lymphocytic leukemia: the cytoskeleton connection. **Scielzo C***, Ten Hacken E, Bertilaccio MT, Muzio M, Calissano C, Ghia P, Caligaris-Cappio F. *Leuk Lymphoma*. 2010 Aug;51(8):1371-4. * **corresponding author** I.F. 2,3. PMID: 20687794
30. An overview of chronic lymphocytic leukaemia biology. Bertilaccio MT, **Scielzo C**, Muzio M, Caligaris-Cappio F. *Best Pract Res Clin Haematol*. 2010 Mar;23(1):21-32.12.005. Review. I.F. 1,8 PMID: 20620968
31. HS1 has a central role in the trafficking and homing of leukemic B cells. **Scielzo C**, Bertilaccio MT, Simonetti G, Dagklis A, ten Hacken E, Fazi C, Muzio M, Caiolfa V, Kitamura D, Restuccia U, Bachi A, Rocchi M, Ponzoni M, Ghia P, Caligaris-Cappio F. *Blood*. 2010 Nov 4;116(18):3537-46. I.F. 13,2. PMID: 20530793
32. MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27. Frenquelli M, Muzio M, **Scielzo C**, Fazi C, Scarfò L, Rossi C, Ferrari G, Ghia P, Caligaris-Cappio F. *Blood*. 2010 May 13;115(19):3949-59. I.F. 13,2. PMID: 20203269
33. A novel Rag2-/-gammac-/-xenograft model of human CLL. Bertilaccio MT, **Scielzo C**, Simonetti G, Ponzoni M, Apollonio B, Fazi C, Scarfò L, Rocchi M, Muzio M, Caligaris-Cappio F, Ghia P. *Blood* 2010 Feb 25;115(8):1605-9. I.F. 13,2. PMID: 20018917
34. Expression and function of toll like receptors in chronic lymphocytic leukaemia cells. Muzio M, **Scielzo C**, Bertilaccio MT, Frenquelli M, Ghia P, Caligaris-Cappio F. *Br J Haematol*. 2009 Feb;144(4):507-16.I.F. 4,92. PMID: 19036098
35. The immunoglobulin gene repertoire of low-count chronic lymphocytic leukemia (CLL)-like monoclonal B lymphocytosis is different from CLL: diagnostic implications for clinical monitoring. Dagklis A, Fazi C, Sala C, Cantarelli V, **Scielzo C**, Massacane R, Toniolo D, Caligaris-Cappio F, Stamatopoulos K, Ghia P. *Blood*. 2009 Jul 2;114(1):26-32. I.F. 13,2. PMID: 19029437
36. Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. Muzio M, Apollonio B, **Scielzo C**, Frenquelli M, Vandoni I, Boussiotis V, Caligaris-Cappio F, Ghia P. *Blood*. 2008 Jul 1;112(1):188-95. I.F. 13,2. PMID: 18292287
37. From normal to clonal B cells: Chronic lymphocytic leukemia (CLL) at the crossroad between neoplasia and autoimmunity. Ghia P, **Scielzo C**, Frenquelli M, Muzio M, Caligaris-Cappio F. *Autoimmun Rev*. 2007 Dec;7(2):127-31. Review I.F. 5,3. PMID: 18035322
38. Age-dependent accumulation of monoclonal CD4+CD8+ double positive T lymphocytes in the peripheral blood of the elderly. Ghia P, Prato G, Stella S, **Scielzo C**, Geuna M, Caligaris-Cappio F. *Br J Haematol*. 2007 Dec;139(5):780-90. I.F. 4,942. PMID: 18021092
39. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Murray F, Darzentas N, Hadzidimitriou A, Tobin G, Boudjogra M, **Scielzo C**, Laoutaris N, Karlsson K, Baran-Marzsak F, Tsaftaris A, Moreno C, Anagnostopoulos A, Caligaris-Cappio F, Vaur D, Ouzounis C, Belessi C, Ghia P, Davi F, Rosenquist R, Stamatopoulos K. *Blood*. 2008 Feb 1;111(3):1524-33. I.F. 13,2. PMID: 17959859

40. HS1 complexes with cytoskeleton adapters in normal and malignant chronic lymphocytic leukemia B cells. Muzio M*, **Scielzo C***, Frenquelli M, Bachi A, De Palma M, Alessio M, Ghia P, Caligaris- Cappio F. Leukemia. 2007 Sep;21(9):2067-70. * **first authors equally contributed** I.F. 11,7. PMID: 17508001
41. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Venneri MA, De Palma M, Ponzoni M, Pucci F, **Scielzo C**, Zonari E, Mazzieri R, Doglioni C, Naldini L. Blood. 2007 Jun 15;109(12):5276-85. I.F. 13,2. PMID: 17327411
42. ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturational stage. **Scielzo C**, Camporeale A, Geuna M, Alessio M, Poggi A, Zocchi MR, Chilosi M, Caligaris-Cappio F, Ghia P. Leukemia. 2006 Apr;20(4):689-95. I.F. 11,7. PMID: 16482211
43. Differential effects on CLL cell survival exerted by different microenvironmental elements. Ghia P, Circosta P, **Scielzo C**, Vallario A, Camporeale A, Granziero L, Caligaris-Cappio F. Curr Top Microbiol Immunol. 2005;294:135-45. Review. I.F. 4,806. PMID: 16323430
44. HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses. **Scielzo C**, Ghia P, Conti A, Bachi A, Guida G, Geuna M, Alessio M, Caligaris- Cappio F. J Clin Invest. 2005 Jun;115(6):1644-5 I.F. 12,7. PMID:15931393
45. CD38 modifications in chronic lymphocytic leukemia: are they relevant? Ghia P, Guida G, **Scielzo C**, Geuna M, Caligaris-Cappio F. Leukemia. 2004 Oct;18(10):1733-5. Review. I.F. 11,7. PMID:15343349
46. Monoclonal CD5+ and CD5- B-lymphocyte expansions are frequent in the peripheral blood of the elderly. Ghia P, Prato G, **Scielzo C**, Stella S, Geuna M, Guida G, Caligaris-Cappio F. Blood. 2004 Mar 15;103(6):2337-42. I.F. 13,2. PMID: 14630808
47. The characterization of chemokine production and chemokine receptor expression reveals possible functional cross-talks in AML blasts with monocytic differentiation. Cignetti A, Vallario A, Roato I, Circosta P, Strola G, **Scielzo C**, Allione B, Garetto L, Caligaris-Cappio F, Ghia P. Exp Hematol. 2003 Jun;31(6):495-503. I.F. 2,907. PMID: 12829025
48. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Ghia P, Guida G, Stella S, Gottardi D, Geuna M, Strola G, **Scielzo C**, Caligaris-Cappio F. Blood. 2003 Feb 15;101(4):1262-9 I.F. 13,2. PMID: 12406914
49. CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5+ Blymphocytes. Granziero L, Circosta P, **Scielzo C**, Frisaldi E, Stella S, Geuna M, Giordano S, Ghia P, Caligaris-Cappio F. Blood. 2003 Mar 1;101(5):1962-9. I.F. 13,2. PMID: 12406905